前列腺增生大鼠模型的建立

Establishment of Prostatic Hyperplasia Model of Rats

目的:探讨丙酸睾酮对去势和不去势SD大鼠前列腺增生的影响。方法:8周龄雄性SD大鼠25只,随机分为正常对照组(n=5)、不去势模型组(n=15)及去势模型组(n=5);不去势模型组按注射丙酸睾酮剂量又分为不去势低剂量组、中剂量组和高剂量组,注射剂量分别为1.25,2.5,5 mg/(kg·d);去势模型组无菌切除双侧睾丸1周后注射丙酸睾酮5 mg/(kg·d);去势模型组和不去势模型组均连续注射丙酸睾酮4周,于末次给药后分离大鼠前列腺,检测其湿重、体积和脏器系数;组织切片HE染色,光镜下观察前列腺组织变化。结果:不去势小剂量组和中剂量组的前列腺湿重、体积和脏器系数增加,与正常对照组相比差异有统计学意义(P<0.05),不去势高剂量组和去势组的前列腺体积和脏器系数与正常对照组相比,差异均具有统计学意义(P<0.01);去势组和不去势组大鼠前列腺体积和腺腔大小均较正常对照组增大,且不去势组前列腺腺体与周围组织界限更清楚,腺腔内乳头状突起也比去势组更加明显。结论:使用不去势、皮下注射5 mg/(kg·d)丙酸睾酮的方法可有效的建立前列腺增生大鼠模型。

Objective：To investigate the effect of testosterone propionate on prostatic hyperplasia in castrated and uncastrated SD rats.Methods：A total of 25 SD male adult rats aged 8 weeks,were equally randomized into 5 groups：normal control group,uncastrated group and castrated group,according to injection dose of testosterone propionate,uncastrated group was divided into low dose group,medium dose group and high dose group,dose were 1.25,2.5 and 5 mg/（kg · d） respectively.Uncastrated group and castrated group received testoterone propionate injection for 4 weeks,to carry out anatomy after the final injection and isolate the prostate.Testing the wet weight,volume and organ coefficient; after histological section,HE dying,and observing the morphological changes of prostate issue by light microscope.Results：The wet weight,volume of prostate and organ coefficient of uncastrated low dose group and medium dose group,compared with that of normal control group,differences have statistical significance （P ＜ 0.05）,and volume of prostate and organ coefficient of uncastrated high dose group and castrated group,differences have statistical significance （P ＜ 0.01）.The volume and the gland cavity of prostate in castrated and uncastrated group were larger compared with the normal control group,the surrounding tissue boundaries and the papillae of prostate gland in uncastrated groups were more visible than the castrated groups.Conclusions：Prostatic hyperplasia model of rats can be established by using the uncastrated and hypodermic injection with testosterone propionate at 5 mg/kg · d.